Upadacitinib
Selective JAK1 inhibitor for arthritis, eczema and inflammatory bowel disease.
- Starts working
- Weeks
- Half-life
- About 8–14 hours
- In use since
- —
- Pregnancy
- Usually avoided
Overview
Upadacitinib is a once-daily JAK1 inhibitor used for rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, atopic dermatitis and IBD. JAK inhibitor warnings apply.
Conditions it's used for
How it works
Calms immune signalling inside cells.
Upadacitinib belongs to the JAK inhibitors. How JAK inhibitors work: block JAK enzymes that pass messages from several inflammation signals into immune cells.
Uses
- Rheumatoid arthritis
- Psoriatic arthritis
- Atopic dermatitis (eczema)
- Crohn's disease
- Ulcerative colitis
Available as: extended-release tablet.
Typical dose
- Adults
- 15 mg once a day (arthritis); higher doses in eczema and IBD.
Typical doses for orientation only. Your prescription, the pack leaflet and local guidance take priority.
Side effects
Common
Often mild and may settle with time
- Upper respiratory infections
- Acne
- Nausea
- Raised cholesterol
- Cold sores
Serious — get medical help
Uncommon, but need prompt attention
- Serious infections
- Blood clots
- Heart attack and stroke
- Cancers
- Bowel perforation
Warnings
- Screen for TB before starting
- Swallow tablets whole
Who should avoid it
- Active serious infection
- Active TB
- Pregnancy
- Severe liver impairment
Interactions
- Ketoconazole, clarithromycin — raised levels
- Rifampicin — lower levels
- Other immunosuppressants — added infection risk
- Live vaccines — avoid
Other medicines in the atlas that need care with Upadacitinib, grouped by the reason:
Reduced effectModerateWith Carbamazepine, Efavirenz, Enzalutamide, Griseofulvin, Modafinil and 5 more
Enzyme induction lowers levels of this medicine, which may stop it working.
What's usually done: Monitor effect; dose changes or alternatives may be needed. The effect lasts weeks after stopping the inducer.
Raised drug levelsModerateWith Clarithromycin, Darunavir, Erythromycin, Itraconazole, Lopinavir-ritonavir and 2 more
Blocking CYP3A4 increases levels of this medicine, so side effects become more likely.
What's usually done: A dose reduction, alternative or extra monitoring may be needed.
Using it safely
- Alcohol
- Best to limit. Alcohol may add to liver strain.
- Food and drink
- With or without food.
- If you miss a dose
- Take when remembered; skip if near the next dose.
- Stopping it
- Only on advice of your specialist.
- Driving
- No effect.
- Tests and checks
- Blood counts; Lipids; Liver tests; Signs of clots
- If too much is taken
- Seek advice.
- Storage
- Room temperature.
- Legal status
- United States: Prescription onlyUnited Kingdom: Prescription-only medicine (POM)India: Schedule HAustralia: Prescription only (Schedule 4)
Pregnancy and breastfeeding
Pregnancy
Usually avoided
Avoid in pregnancy.
Breastfeeding
Usually avoided
Avoid.
Special groups
- Kidney disease
- Dose adjustment may be needed.
- Liver disease
- Avoid in severe impairment.
- Older adults
- Use caution; higher risks.
Brand names
- United States
- Rinvoq
- United Kingdom
- Rinvoq
- India
- Rinvoq
- Australia
- Rinvoq
Examples only; many generic versions exist. The same brand name can mean different products in different countries.
Common questions
Do I need a prescription for Upadacitinib?
Yes — Upadacitinib is prescription-only in most countries.
Can I take Upadacitinib during pregnancy?
Usually avoided. Avoid in pregnancy. Always check with a doctor or midwife.
How quickly does Upadacitinib work?
Weeks.
Related medicines
Sources and official information
- MedlinePlus (US National Library of Medicine)
- DailyMed — official US labels
- NHS medicines A–Z
- WHO ATC/DDD index — L04AA44
Entry last reviewed October 2026. Compiled from WHO, NHS, FDA/DailyMed, BNF and national formulary information. How we write entries.